Integrating HCV Treatment for Medical and Behavioral Health Providers A Virtual Preceptor Program
This course is designed for medical professionals who are interested in providing onsite treatment and cure to people living with HCV. It covers medication management and considerations including drug interactions, patients with co-occurring conditions, social drivers of health and substance use disorders. The training also provides information on prior authorization removal for Pennsylvania, patient education resources and treatment adherence strategy recommendations. Priority registration is given to providers practicing in Philadelphia. The first session is didactic, and the second session is a clinical case discussion on HCV mono-infected patients.
Registration: https://www.maaetc.org/events/view/27211
Please note registration for this event includes the Didactic Half-Day on Wednesday, February 12, 2025 from 8:45 am - 1:30 pm and the Half-Day Clinical Case Discussion on Wednesday, February 19, 2025 from 9:00 am - 2:00 pm.
AUDIENCE
Providers of any specialty interested in treating people living with HCV, including, but not limited to, physicians, nurse practitioners, physician assistants, pharmacists and nurses.
FEE
Free Admission
FACULTY
Includes Jay Kostman, MD (Medical Director, John Bell Health Center, Philadelphia FIGHT Community Health Centers); Katie Huynh, PA-C, MS, AAHIVM-S (Coordinator of HIV Services, Delaware Valley Community Health, Inc., Fairmount Primary Care Center at Girard Medical Center); David Koren, PharmD, BCPS, AAHIVP (Clinical Pharmacist Specialist - Infectious Diseases/HIV, Temple University Hospital); Jody Gilmore, MSN, CRNP (Prevention Point Philadelphia); Alexandra Ripkin (Director of Integrated Care, Merakey).
CME Program Code: 22254
TARGET AUDIENCE
Physicians, nurse practitioners, pharmacists, advanced practice nurses, nurses, physician assistants and staff who provide HCV care
LEARNING OBJECTIVES
Participants will be able to:
- Describe medical management of HCV
- Identify when to initiate change in medications and manage complications
- Apply current research for patients with a substance use disorder
This program is sponsored in collaboration with the Viral Hepatitis Program (Division of Disease Control) of the Philadelphia Department of Public Health.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Drexel University College of Medicine and the MidAtlantic AIDS Education and Training Center of the Health Federation of Philadelphia. The Drexel University College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement: The Drexel University College of Medicine designates this live activity for a maximum of 8.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AOA: This program is eligible for 8.0 credits in Category 2A of the American Osteopathic Association.
FACULTY DISCLOSURE STATEMENT
It is the policy of Drexel University College of Medicine to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational programs. Speakers at continuing medical education activities are required to disclose to the audience, any relevant commercial interest (which is any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients). Any conflicts of interest must be resolved prior to the presentation and announced to the audience. The intent of this disclosure is to allow participants to form their own judgments about the educational content of this activity and determine whether the speaker’s commercial interests influenced the presentation. In addition, speakers are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation.
FACULTY DISCLOSURES
Jay Kostman, MD, is on the speaker bureaus of Abbvie and Gilead Sciences. David Koren, PharmD, BCPS, AAHIVP is on the advisory board for Gilead Sciences, ViiV, and Thera Technologies and is an independent contractor for Abbvie and Thera Technologies. Jody Gilmore, ANP-BC is on the speaker bureau of Gilead Sciences and Abbvie. All three faculty will attest that clinical recommendations are evidence-based and free of commercial bias.
PLANNING COMMITTEE DISCLOSURES
James Dean, MD, Yelena Galkin, MD, and Debra D’Alessandro, MPH have no commercial relationships to disclose.
Supported by a grant from the Health Resources and Services Administration (HRSA),
HIV/AIDS Bureau, Office of Program Support,
No. U1OHA29295
Registration: https://www.maaetc.org/events/view/27211
For more information about this program, connect with:
Tiania Warner, MS
Director of HIV Training, MidAtlantic AIDS Education and Training Center
Regional Partner, Health Federation of Philadelphia
Phone: 215.246.5298
Email: twarner@healthfederation.org